Poseida Therapeutics, Inc. (PSTX) Financials

$0.00

$0 (0%)
Last update: 07:00 PM EST
Day's range
$9.49
Day's range
$9.67
$150M$150M$100M$100M$50M$50M$0$0-$50M-$50M-$100M-$100M-$150M-$150MEarning2017201720182018201920192020202020212021202220222023202325000%25000%20000%20000%15000%15000%10000%10000%5000%5000%0%0%-5000%-5000%Profit Margin
Profit Margin
Revenue
Earnings

PSTX Income statement / Annual

Last year (2023), Poseida Therapeutics, Inc.'s total revenue was $64.70 M, a decrease of 50.37% from the previous year. In 2023, Poseida Therapeutics, Inc.'s net income was -$123.43 M. See Poseida Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.

Period FY-2023 FY-2022 FY-2021 FY-2020 FY-2019 FY-2018 FY-2017 FY-2016
Period Ended 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016
Operating Revenue $64.70 M $130.36 M $31.24 K $0.00 $0.00 $0.00 $2.99 M $9.77 M
Cost of Revenue $156.77 M $5.17 M $4.55 M $2.59 M $1.19 M $689.00 K $0.00 $0.00
Gross Profit -$92.07 M $125.19 M -$4.52 M -$2.59 M -$1.19 M -$689.00 K $2.99 M $9.77 M
Gross Profit Ratio -1.42 0.96 -144.72 0 0 0 1 1
Research and Development Expenses $156.77 M $152.90 M $136.73 K $103.52 K $60.39 M $30.88 M $19.10 M $9.86 M
General & Administrative Expenses $37.44 M $37.54 M $35.92 K $23.03 K $18.46 M $9.67 M $5.48 M $5.35 M
Selling & Marketing Expenses $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 -$220.00 K
Selling, General & Administrative Expenses $37.44 M $37.54 M $35.92 K $23.03 K $18.46 M $9.67 M $5.48 M $5.13 M
Other Expenses $0.00 $2.86 M $19.80 K $280.00 $2.56 M -$821.00 K $37.00 K $0.00
Operating Expenses $194.21 M $190.44 M $172.65 K $126.55 K $78.85 M $40.56 M $24.58 M $15.00 M
Cost And Expenses $179.36 M $190.44 M $172.65 K $126.55 K $78.85 M $40.56 M $24.58 M $15.22 M
Interest Income $0.00 $6.37 M $3.36 M $3.51 M $1.55 M $0.00 $0.00 $0.00
Interest Expense $8.67 M $6.37 M $3.36 K $3.51 K $3.55 M $1.80 M $558.00 K $0.00
Depreciation & Amortization $5.61 M $5.17 M $4.55 M $2.59 M $1.19 M $689.00 K $676.00 K $220.00 K
EBITDA -$109.04 M -$54.77 M -$117.06 M -$145.48 M -$91.68 M -$45.12 M -$20.88 M -$5.12 M
EBITDA Ratio -1.69 -0.42 -3747.49 0 0 0 -6.99 -0.52
Operating Income Ratio -2 -0.46 -4.53 0 0 0 -6.59 -0.56
Total Other Income/Expenses Net $6.18 M -$3.51 M $16.44 M -$129.65 M -$7.68 M -$2.62 M $1.40 M $109.00 K
Income Before Tax -$123.32 M -$63.46 M -$124.97 K -$129.78 K -$86.53 M -$44.61 M -$20.19 M -$5.34 M
Income Before Tax Ratio -1.91 -0.49 -4 0 0 0 -6.76 -0.55
Income Tax Expense $107.00 K $544.00 K -$4.53 M -$2.58 M $6.11 M -$202.00 K -$527.00 K -$765.00 K
Net Income -$123.43 M -$64.00 M $4.40 M $2.45 M -$92.64 M -$44.40 M -$19.66 M -$4.58 M
Net Income Ratio -1.91 -0.49 140.98 0 0 0 -6.59 -0.47
EPS -1.37 -0.89 0.0708 0.0681 -2.33 -1.24 -0.49 -0.0771
EPS Diluted -1.37 -0.89 0.0708 0.0681 -2.33 -1.24 -0.49 -0.0771
Weighted Average Shares Out $90.19 M $71.91 M $62.18 M $36.00 M $39.73 M $35.93 M $39.73 M $59.32 M
Weighted Average Shares Out Diluted $90.19 M $71.95 M $62.24 M $36.00 M $39.73 M $35.93 M $39.73 M $59.32 M
Link